logo
#

Latest news with #JulissaViana

Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Oncology to Present at Upcoming Investor Conferences

Associated Press

time01-05-2025

  • Business
  • Associated Press

Verastem Oncology to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--May 1, 2025-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May: A live webcast of the fireside chats can be accessed under events on Verastem Oncology's website at A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small-molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit and follow us on LinkedIn. View source version on CONTACT: For Investor and Media Inquiries: Julissa Viana Vice President, Corporate Communications, Investor Relations & Patient Advocacy [email protected] [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY SOURCE: Verastem Oncology Copyright Business Wire 2025. PUB: 05/01/2025 07:30 AM/DISC: 05/01/2025 07:32 AM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store